Innovent Biologics (HK:1801)
:1801
Want to see HK:1801 full AI Analyst Report?
1801 Stock Chart & Stats
HK$91.50
-HK$0.85(-2.50%)
At close: 4:00 PM EST
HK$91.50
-HK$0.85(-2.50%)
Day’s Range― - ―
52-Week RangeHK$54.50 - HK$109.10
Previous CloseN/A
Volume9.75M
Average Volume (3M)16.11M
Market Cap
HK$138.02B
Enterprise ValueHK$105.10B
Total Cash (Recent Filing)HK$18.24B
Total Debt (Recent Filing)HK$2.82B
Price to Earnings (P/E)145.7
Beta0.67
Next Earnings
Aug 26, 2026EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding1,738,237,200
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$118.69Price Target Upside29.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.39
Revenue Forecast (FY)HK$18.17B
Bulls Say, Bears Say
Bulls Say
2025 Financial InflectionThe 2025 inflection — revenue up to 12.7B and a positive net income (0.79B) — indicates the company has transitioned from development losses toward commercial scale. Sustained revenue and recurring product sales can fund R&D, support pipeline progression, and reduce reliance on external financing over the medium term.
High Gross Margins & Product EconomicsAn ~86.5% gross margin reflects strong product economics typical of biologics and effective manufacturing/commercial execution. High gross margins provide durable operating leverage: as sales grow, more revenue converts to operating cash, supporting margin sustainability, reinvestment in pipeline and competitive pricing flexibility.
Strong Cash Generation & Lower LeverageThe sharp 2025 improvement to 10.0B OCF and 9.3B FCF plus a low debt-to-equity (~0.15) materially strengthens financial flexibility. Consistent positive free cash flow and conservative leverage allow self-funding of late-stage trials and commercialization, lowering refinancing risk and enabling strategic investments over multiple quarters.
Bears Say
Uneven Historical Cash GenerationAlthough 2025 cash flow is strong, multi-year negative operating and free cash flow through 2024 shows volatility in cash generation. This uneven track record raises the risk that 2025's cadence may include timing effects or one-off items, so sustained FCF must be proven across multiple quarters to be durable.
Prior Multi-year Operating LossesA history of negative operating margins through 2024 signals execution and scale-up risks inherent to biologics commercialization. Returning to and maintaining positive operating margins requires sustained volume growth and controlled SG&A/R&D investment; any slowdown could quickly reintroduce losses given prior operating volatility.
Concentration On China Market & Reimbursement RiskHeavy reliance on the China commercialization channel concentrates exposure to national reimbursement policy, hospital tendering, and pricing pressure. Structural shifts in reimbursement or procurement could materially affect revenues and growth visibility; diversification or durable reimbursement status is needed to reduce this country-level concentration risk.
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$54.50 and its highest was HK$109.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$138.02B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2026. The company reported -HK$0.011 earnings per share for the quarter, missing the consensus estimate of HK$0.138 by -HK$0.149.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.86.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,738,237,200 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -HK$0.011 in its last earnings report, missing expectations of HK$0.138. Following the earnings report the stock price went down -3.816%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
80.58%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
1801 Stock 12 Month Forecast
Average Price Target
HK$118.69
▲(29.72% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---